Clinical Trials Logo
  1. Home
  2. Gastrointestinal Stromal Tumor
  3. NCT01316263

A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumor (GIST) Clinical Trial

Official title:
A Phase 2 Study of a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (GIST)

Clinical Trial Summary

The purpose of this study is to evaluate the tumor response of stable disease (SD) partial response, or complete response (according to RECIST 1.1 criteria) at 12 weeks in patients with Gastrointestinal Stromal Tumors (GIST) harboring PDGFRα mutations and patients with GIST not harboring PDGFRα mutations.

Clinical Trial Description

This trial is currently seeking participants with PDGFRα-mutations only. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01316263
Study type Interventional
Source ImClone LLC
Contact
Status Completed
Phase Phase 2
Start date August 2011
Completion date November 2012
View Details
See also
  Status Clinical Trial Phase
Completed NCT02574663 - TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors Phase 1
Active, not recruiting NCT01991379 - MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) Phase 1/Phase 2
Completed NCT01135849 - B-Receptor Signaling in Cardiomyopathy N/A
Completed NCT00623831 - A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen Phase 1
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Completed NCT01294202 - A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST Phase 2
Completed NCT00785785 - A Study of Nilotinib Versus Imatinib in GIST Patients Phase 3
Recruiting NCT02443948 - Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST) N/A
Recruiting NCT01034670 - Advanced Gastrointestinal Endoscopic Imaging N/A
Completed NCT00867113 - Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) Phase 2
Active, not recruiting NCT01391611 - Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) Phase 2
Terminated NCT02452424 - A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Phase 1/Phase 2
Recruiting NCT03594422 - A Study of HQP1351 in Patients With GIST or Other Solid Tumors Phase 1
Recruiting NCT05453292 - Endoscopic Ultrasound Radiofrequency Ablation for GISTs N/A
Completed NCT00780494 - Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma Phase 2
Recruiting NCT04557969 - Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Completed NCT03404076 - Unifying Advanced Treatment With Advanced Imaging
Recruiting NCT04821895 - Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients
Terminated NCT00767234 - Permission to Collect Blood Over Time for Research N/A
Recruiting NCT01048281 - Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma